Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats

Nephron

Volumn 72, Issue 4, 1996, Pages 667-672

  Okada, Hirokazu ^a   Suzuki, Hiromichi ^a   Kanno, Yoshihiko ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adriamycin induced nephropathy; Glomerulosclerosis; Proteinuria; Vasopressin

Indexed keywords

DOXORUBICIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULOPATHY; HISTOPATHOLOGY; KIDNEY DISEASE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; BODY WEIGHT; DOXORUBICIN; EATING; KIDNEY; KIDNEY DISEASES; MALE; PROTEINURIA; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 0029988322     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188957     Document Type: Article

References (23)

1. Okuda S, Oh Y. Tsuruda H, Onoyama K. Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986:29:502-510.
2. Brenner BM. Meyer TW. Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodvnamical-ly mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659.
3. Anderson S. Meyer TW. Rennkc HG. Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985:76:612-619.
4. Zatz R. Dunn BR. Meyer TW, Anderson S. Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986:77:1925-1930.
5. O'Donnell MP. Michels L. Kasiske B. Raij L. Keane WF: Adriamycin-induced chronic proteinuria: A structural and functional study. J Lab Clin Med 1985:106:62-67.
6. Beukcrs JJB. Hoedcmaker PJ. Weening JJ: A comparison of the effects of converting enzyme inhibition and protein restriction in experimental nephrosis. Lab Invest 1988:59:631-641.
7. Fogo A. Yoshida Y. Glick AD. Homma T. Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988:82:322-330.
8. Scholey JW. Miller PL. Rennke HG. Meyer TW: Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy. Kidney Int 1989:36:816-822.
9. Podjarny E, Bernheim JL. Pomcranz A. Rathaus M. Pomcranz M. Green J. Bernheim J: Effect of timing of antihypertensive therapy on glomerular injury: Comparison between capto-pril and diltiazem. Nephrol Dial Transplant 1993:8:501-506.
10. Bankir L, Ahloulay M, Bouby N. Trinh TTM. Machet F. Lacour B. Jüngers P: Is the process of urinary urea concentration responsible fora high glomerular filtration rate? J Am Soc Nephrol 1993:4:1091-1103.
11. Bouby N. Bachmann S. Bichel D. Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrcctomizcd rat. Am J Physiol 1990:258:F973-F979.
12. Edwards RM. Trizna W. Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989:256: F274-F278.
13. Wolthuis A. Boes A. Rodemann HP. Grand J: Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992:41:124-131.
14. Yamamura Y. Ogawa H. Chihara T. Kondo K. Onogawa T. Nakamura S, Mori T. Tominaga M. Yabuuehi Y: OPC-21268. an orally effective. nonpeptide vasopressin V1 receptor antagonist. Science 1991:252:572-574.
15. Burrell LM. Phillips PA. Stephenson J. Risva-nis J, Hutchins AM. Johnston CL: Characterization of a novel non-peptide vasopressin VI receptor antagonist (OPC-21268) in the rat. J Endocrinol 1993:138:259-266.
16. Ohnishi A. Ko Y. Fujihara H. Miyamoto G, Okada K, Odomi M: Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptidc orally active vasopressin V1 receptor antagonist, in humans. J Clin Pharmacol 1993:33:230-238.
17. Yamamura Y. Ogawa H, Yamashita H. Chihara T. Miyamoto H. Nakamura S. Onogawa T. Yamashita T, Hosokawa T. Mori T. Tominaga M. Yabuuehi Y: Characterization of a novel aquaretic agent. OPC-31260. as an orally effective, nonpeptidc vasopressin V2 receptor antagonist. Br J Pharmacol 1992:105:787-791.
18. Ohnishi A. Ohla Y. Okahara R. Fujihara H. Inoue T, Yamamura Y. Yabuuehi Y. Tanaka T: Potent aquaretic agent: A novel nonpeptidc selective vasopressin V2 antagonist (OPC-31260) in men. J Clin Invest 1993:92:2653-2659.
19. Okada H. Suzuki H. Kanno Y. Yamamura V. Saruta T: Chronic, and selective vasopressin blockade in spontaneously hypertensive rats Am J Physiol 1994:267:R1467-R1471.
20. Okada H. Suzuki H. Konishi K. Sakaguchi H Saruta T: Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol 1992:37:235-238.
21. Franco R. Gut A. Ferrari SA. Georgette J. Gav-ras I. Gavras H: Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. Hypertension 1994:23(suppl l):1-246-1-249.
22. Jamil KMA, Watanabc T. Nakao A. Okuda T. Kurokawa K: Distinct mechanisms of action of VI antagonists OPC-21268 and [d(CH2)5Tyr-(Mc)AVP] in mesangial cells. Biochcm Biophys ResCommun 1993:193:738-743.
23. Hourani SMO, Cusack NJ: Pharmacological receptors on blood platelets. Pharmacol Rev 1991:43:243-298.